Silver Elephant Mining Corp. completed the first closing of a non-brokered private placement, raising $840,000 by issuing 7 million units at $0.12 each. Each unit includes one common share and one warrant exercisable at $0.16 for three years. Insider John Lee subscribed for 1.5 million units, with the offering proceeds mainly intended for general working capital. The securities are subject to a four-month hold period under Canadian law, supporting the company's ongoing exploration projects in Kentucky and Bolivia.
Silver Elephant's recent private placement is presented here with Pluang's Basic Materials sector data as of Oct 13, 2026 22:02 WIB. Among 62 priced US Basic Materials stocks on Pluang, 22 rose and 40 fell. Notable prices include MP Materials at USD 42.26 with a 1-day change of -2.54%, BHP Billiton Limited at USD 84.69 down 2.34%, and Equinox Gold Corp. at USD 10.94 down 2.32%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
